Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
87.32
+2.57 (3.03%)
At close: Jun 26, 2026, 4:00 PM EDT
87.28
-0.04 (-0.05%)
After-hours: Jun 26, 2026, 7:54 PM EDT
Corcept Therapeutics Employees
Corcept Therapeutics had 730 employees as of December 31, 2025. The number of employees increased by 230 or 46.00% compared to the previous year.
Employees
730
Change (1Y)
230
Growth (1Y)
46.00%
Revenue / Employee
$1,053,556
Profits / Employee
$63,947
Market Cap
9.37B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| ImmunityBio | 691 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
| Immunovant | 315 |
| Krystal Biotech | 295 |
| Summit Therapeutics | 265 |
| Apogee Therapeutics | 261 |
CORT News
- 10 days ago - Corcept Therapeutics resubmits NDA for Relacorilant in Cushing’s Syndrome - TheFly
- 10 days ago - Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome - Business Wire
- 20 days ago - Corcept announces presentation of new data from Catalyst, Momentum trials - TheFly
- 4 weeks ago - Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure - Business Wire
- 4 weeks ago - Corcept Therapeutics price target raised to $135 from $110 at Canaccord - TheFly
- 4 weeks ago - Corcept Therapeutics price target raised to $95 from $75 at H.C. Wainwright - TheFly
- 4 weeks ago - Corcept Therapeutics to resubmit NDA to U.S. FDA for relacorilant - TheFly
- 4 weeks ago - Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome - Business Wire